Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2022.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circular reasoning concerning Red flags for predicting rituximab response in OCD.
Mol Psychiatry
January 2025
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Clinical Manifestations.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Boston, MA, USA.
Background: In cognitively unimpaired (CU) older adults, the presence of a subjective cognitive decline (SCD) combined with evidence of abnormal b-amyloid (Ab) is proposed as stage 2 of Alzheimer's disease (AD) by the NIA-AA framework (Jack et al., 2018). However, the associations found between SCD and preclinical AD are inconsistent across studies, highlighting the importance of better understanding which specific SCD features are associated with either Ab or tau burden.
View Article and Find Full Text PDFEfficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
Obstet Gynecol
January 2025
Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and Famcru, Department of Paediatrics and Child Health, University of Stellenbosch, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Vaccine Research and Development, Pfizer Ltd, Marlow, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, and iTrials-Hospital Militar Central and iTrials, Buenos Aires, Argentina; Clinical Research Prime, Idaho Falls, Idaho; Boeson Research, Missoula, Montana; Meridian Clinical Research, Hastings, Nebraska; Asian Hospital and Medical Center, Manila, the Philippines; Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Department of Pediatrics, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, and the ReSViNET Foundation, Zeist, the Netherlands; Meilahti Vaccine Research Center MeVac, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Taiwan University Hospital, Taipei, Taiwan; the Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, Japan; Institute of Biomedical Sciences, University of Chile School of Medicine, Santiago, Chile; University of Otago and New Zealand Clinical Research, Christchurch, New Zealand; CHU Sainte-Justine, Montreal, Quebec, Canada; Hospital Moinhos de Vento and Pontifícia Universidade Católica RGS, Porto Alegre, Brazil; the Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Arké SMO S.A. de C.V., Mexico City, Mexico; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, and Perth Children's Hospital, Nedlands, Western Australia, and Vaccine Clinical Research, Pfizer Inc, Sydney, Australia; and Worldwide Safety, Pfizer Srl, Milan, Italy.
Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).
Methods: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose.
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected.
View Article and Find Full Text PDFDupilumab induced ocular surface diseases: an analysis of FAERS database, literature review and disease-gene interaction networks.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Background: Adverse events (AE) in dupilumab-induced ocular surface diseases (DIOSD) have raised concerns regarding its safety. The objective of this study was to evaluate DIOSD by employing database analysis and clinical case review, along with mechanism analysis.
Research Design And Methods: Database AE data were extracted from FAERS from 2017 Quarter 1 (Q1) to 2023 Q1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!